China Oncology ›› 2024, Vol. 34 ›› Issue (5): 485-492.doi: 10.19401/j.cnki.1007-3639.2024.05.005
• Article • Previous Articles Next Articles
ZHANG Ruoxin(), YE Zilan, WENG Junyong, LI Xinxiang(
)
Received:
2024-02-02
Revised:
2024-04-25
Online:
2024-05-30
Published:
2024-06-07
Contact:
LI Xinxiang
Share article
CLC Number:
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang. Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients[J]. China Oncology, 2024, 34(5): 485-492.
Tab. 1
Clinicopathological characteristics of patients [n (%)]"
Characteristic | Age≤73 years old (n=2 820) | Age>73 years old (n=494) | P value |
---|---|---|---|
Age/year $\bar{x} \pm s$ | 57.36±9.995 | 78.22±3.570 | |
Gender | 0.545 | ||
Male | 1 777 (63.0) | 304 (61.5) | |
Female | 1 043 (37.0) | 190 (38.5) | |
Location | 0.061 | ||
Rectum | 1 196 (42.4) | 192 (38.9) | |
Left colon | 699 (24.8) | 131 (26.5) | |
Right colon | 916 (32.5) | 170 (34.4) | |
Unknown | 9 (0.3) | 1 (0.2) | |
Differentiation | 0.359 | ||
Poor | 547 (19.4) | 113 (22.9) | |
Moderate | 2 183 (77.4) | 366 (74.1) | |
Well | 32 (1.1) | 5 (1.0) | |
Unknown | 58 (2.1) | 10 (2.0) | |
Intravascular invasion | 0.791 | ||
- | 2 586 (91.7) | 455 (92.1) | |
+ | 234 (8.3) | 39 (7.9) | |
Neural invasion | 0.087 | ||
- | 2 388 (84.7) | 433 (87.7) | |
+ | 432 (15.3) | 61 (12.3) | |
pT stage | 0.456 | ||
3 | 1 147 (40.7) | 192 (38.9) | |
4 | 1 673 (59.3) | 302 (61.1) |
Tab. 2
Univariate and multivariate COX regression analysis"
OS | DFS | ||||||||
---|---|---|---|---|---|---|---|---|---|
Univariate P value | Multivariate analysis | Univariate P value | Multivariate analysis | ||||||
HR | 95% CI | P value | HR | 95% CI | P value | ||||
Age/year | |||||||||
≤73 | <0.001 | — | <0.001 | — | |||||
>73 | 3.667 | 2.946-4.565 | <0.001 | 2.368 | 1.953-2.872 | <0.001 | |||
Gender | |||||||||
Female | 0.026 | — | 0.028 | — | |||||
Male | 1.272 | 1.018-1.591 | 0.035 | 1.200 | 1.001-1.440 | 0.049 | |||
Location | |||||||||
Rectum | 0.513 | — | 0.128 | — | |||||
Left colon | 0.824 | 0.626-1.085 | 0.167 | 0.809 | 0.648-1.011 | 0.062 | |||
Right colon | 0.894 | 0.701-1.140 | 0.365 | 0.831 | 0.679-1.017 | 0.073 | |||
Differentiation | |||||||||
Well | 0.45 | — | 0.04 | — | |||||
Median | 1.046 | 0.418-2.613 | 0.924 | 1.181 | 0.517-2.698 | 0.692 | |||
Poor | 0.945 | 0.387-2.306 | 0.901 | 0.952 | 0.679-1.017 | 0.073 | |||
pT stage | |||||||||
3 | 0.217 | — | 0.562 | — | |||||
4 | 1.127 | 0.849-1.495 | 0.408 | 1.047 | 0.856-1.279 | 0.655 | |||
Lymphovasclular invasion | |||||||||
No | 0.029 | — | 0.001 | — | |||||
Yes | 1.360 | 0.963-1.922 | 0.081 | 1.455 | 1.108-1.911 | 0.007 | |||
Neural invasion | |||||||||
No | 0.019 | — | <0.001 | — | |||||
Yes | 1.504 | 1.132-1.999 | 0.005 | 1.599 | 1.279-1.999 | <0.001 |
[1] | MILLER K D, NOGUEIRA L, DEVASIA T, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436. |
[2] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
[3] | KIM J H. Chemotherapy for colorectal cancer in the elderly[J]. World J Gastroenterol, 2015, 21(17): 5158-5166. |
[4] | ZHANG H, HU H Q, HUANG R, et al. Natural orifice specimen extraction surgery versus conventional laparoscopic-assisted resection for colorectal cancer in elderly patients: a propensity-score matching study[J]. Updates Surg, 2022, 74(2): 599-607. |
[5] |
BETESH A L, SCHNOLL-SUSSMAN F H. Colorectal cancer screening in the elderly[J]. Clin Geriatr Med, 2021, 37(1): 173-183.
doi: 10.1016/j.cger.2020.08.012 pmid: 33213771 |
[6] | KANNARKATT J, JOSEPH J, KURNIALI P C, et al. Adjuvant chemotherapy for stage Ⅱ colon cancer: a clinical dilemma[J]. J Oncol Pract, 2017, 13(4): 233-241. |
[7] | SCHRAG D, RIFAS-SHIMAN S, SALTZ L, et al. Adjuvant chemotherapy use for medicare beneficiaries with stage Ⅱ colon cancer[J]. J Clin Oncol, 2002, 20(19): 3999-4005. |
[8] | FONTANA E, MEYERS J, SOBRERO A, et al. Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant fluoropyrimidine and oxaliplatin[J]. J Clin Oncol, 2021, 39(36): 4009-4019. |
[9] | ANDRÉ T, MEYERHARDT J, IVESON T, et al. Effect of duration of adjuvant chemotherapy for patients with stage Ⅲ colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials[J]. Lancet Oncol, 2020, 21(12): 1620-1629. |
[10] | PETRELLI F, LABIANCA R, ZANIBONI A, et al. Assessment of duration and effects of 3 vs 6 months of adjuvant chemotherapy in high-risk stage Ⅱ colorectal cancer: a subgroup analysis of the TOSCA randomized clinical trial[J]. JAMA Oncol, 2020, 6(4): 547-551. |
[11] |
IVESON T J, KERR R S, SAUNDERS M P, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial[J]. Lancet Oncol, 2018, 19(4): 562-578.
doi: S1470-2045(18)30093-7 pmid: 29611518 |
[12] | MIMA K, KURASHIGE J, MIYANARI N, et al. Advanced age is a risk factor for recurrence after resection in stage Ⅱ colorectal cancer[J]. In Vivo, 2020, 34(1): 339-346. |
[13] | NAGTEGAAL I D. Never too old to fight cancer? What do we know about colorectal cancer in the elderly?[J]. Colorectal Dis, 2017, 19(3): 223. |
[14] |
NITSCHE U, SPÄTH C, MÜLLER T C, et al. Colorectal cancer surgery remains effective with rising patient age[J]. Int J Colorectal Dis, 2014, 29(8): 971-979.
doi: 10.1007/s00384-014-1914-y pmid: 24924447 |
[15] | HE J N, BIAN X H, SONG C X, et al. High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: a large-scale cohort study[J]. Cardiovasc Diabetol, 2022, 21(1): 156. |
[16] | SHI Q, ANDRE T, GROTHEY A, et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages Ⅱ and Ⅲ colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database[J]. J Clin Oncol, 2013, 31(29): 3656-3663. |
[17] | HOSHINO N, HASEGAWA S, HIDA K, et al. Nomogram for predicting recurrence in stage Ⅱ colorectal cancer[J]. Acta Oncol, 2016, 55(12): 1414-1417. |
[18] | BENSON A B 3rd, SCHRAG D, SOMERFIELD M R, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage Ⅱ colon cancer[J]. J Clin Oncol, 2004, 22(16): 3408-3419. |
[19] | BENSON A B, VENOOK A P, AL-HAWARY M M, et al. NCCN guidelines insights: colon cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4): 359-369. |
[20] | BENSON A B 3rd, VENOOK A P, CEDERQUIST L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(3): 370-398. |
[21] |
CASTLE S C. Clinical relevance of age-related immune dysfunction[J]. Clin Infect Dis, 2000, 31(2): 578-585.
doi: 10.1086/313947 pmid: 10987724 |
[22] |
UHRLAUB J L, SMITHEY M J, NIKOLICH-ŽUGICH J. Cutting edge: the aging immune system reveals the biological impact of direct antigen presentation on CD8 T cell responses[J]. J Immunol, 2017, 199(2): 403-407.
doi: 10.4049/jimmunol.1700625 pmid: 28615415 |
[23] | LI G, SMITHEY M J, RUDD B D, et al. Age-associated alterations in CD8α+ dendritic cells impair CD8 T-cell expansion in response to an intracellular bacterium[J]. Aging Cell, 2012, 11(6): 968-977. |
[24] | CASTLE S, UYEMURA K, WONG W, et al. Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents[J]. Mech Ageing Dev, 1997, 94(1/2/3): 7-16. |
[25] | WANG C, YUAN Y, ZHENG M Y, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality[J]. J Am Coll Cardiol, 2020, 75(23): 2921-2930. |
[26] |
SORRENTINO M F, KIM J, FODERARO A E, et al. 5-fluorouracil induced cardiotoxicity: review of the literature[J]. Cardiol J, 2012, 19(5): 453-458.
pmid: 23042307 |
[27] | JENSEN S A, SØRENSEN J B. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity[J]. Cancer Chemother Pharmacol, 2012, 69(1): 57-64. |
[28] |
VAN CUTSEM E, HOFF P M, BLUM J L, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil[J]. Ann Oncol, 2002, 13(3): 484-485.
doi: 10.1093/annonc/mdf108 pmid: 11996484 |
[29] | Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group[J]. Lancet, 2000, 356(9234): 968-974. |
[30] |
FORMICA V, ZANIBONI A, LOUPAKIS F, et al. Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. how should IDEA findings affect clinical practice?[J]. Int J Cancer, 2018, 143(10): 2342-2350.
doi: 10.1002/ijc.31616 pmid: 29873066 |
[31] |
FELIU J, SERENO M, CASTRO J D, et al. Chemotherapy for colorectal cancer in the elderly: whom to treat and what to use[J]. Cancer Treat Rev, 2009, 35(3): 246-254.
doi: 10.1016/j.ctrv.2008.11.004 pmid: 19345021 |
[32] | BRAGA M, GIANOTTI L, VIGNALI A, et al. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer[J]. Surgery, 2002, 132(5): 805-814. |
[33] |
GIANOTTI L, BRAGA M, NESPOLI L, et al. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer[J]. Gastroenterology, 2002, 122(7): 1763-1770.
doi: 10.1053/gast.2002.33587 pmid: 12055582 |
[34] | CHEN Y, LIU B L, SHANG B, et al. Nutrition support in surgical patients with colorectal cancer[J]. World J Gastroenterol, 2011, 17(13): 1779-1786. |
[35] |
MIYATA H, YANO M, YASUDA T, et al. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer[J]. Clin Nutr, 2012, 31(3): 330-336.
doi: 10.1016/j.clnu.2011.11.002 pmid: 22169459 |
[36] |
MIYATA H, YANO M, YASUDA T, et al. Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer[J]. Nutrition, 2017, 33: 204-210.
doi: S0899-9007(16)30124-1 pmid: 27644137 |
[1] | HUANG Haozhe, CHEN Hong, ZHENG Dezhong, CHEN Chao, WANG Ying, XU Lichao, WANG Yaohui, HE Xinhong, YANG Yuanyuan, LI Wentao. A CT-based radiomics nomogram for predicting local tumor progression of colorectal cancer lung metastases treated with radiofrequency ablation [J]. China Oncology, 2024, 34(9): 857-872. |
[2] | WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi. Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model [J]. China Oncology, 2024, 34(9): 873-880. |
[3] | XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan. Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma [J]. China Oncology, 2024, 34(8): 726-733. |
[4] | GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo. The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer [J]. China Oncology, 2024, 34(8): 745-752. |
[5] | WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang. Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases [J]. China Oncology, 2024, 34(6): 527-536. |
[6] | LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui. Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy [J]. China Oncology, 2024, 34(3): 278-285. |
[7] | LI Jun, LU Tingwei, FANG Xuqian. Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer [J]. China Oncology, 2024, 34(11): 1061-1066. |
[8] | WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong. Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells [J]. China Oncology, 2024, 34(11): 987-997. |
[9] | OUYANG Fei, WANG Yang, CHEN Yu, PEI Guoqing, WANG Ling, ZHANG Yang, SHI Lei. Construction of the prediction model of breast cancer bone metastasis based on machine learning [J]. China Oncology, 2024, 34(10): 903-914. |
[10] | ZHANG Shaohua, LI Zhening, WANG Wei, WEI Yifan, HONG Yonggang, HAO Liqiang. Research progress in the related treatment of KRAS mutant colorectal cancer [J]. China Oncology, 2024, 34(10): 979-986. |
[11] | Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association . Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition) [J]. China Oncology, 2024, 34(1): 13-66. |
[12] | WU Han, XU Lei, WANG Miaomiao, ZHANG Ruizhe, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlation of LC3 and the recruitment of dendritic cell and the formation of TLS in colorectal cancer and its clinical significance [J]. China Oncology, 2023, 33(9): 818-828. |
[13] | JIN Yizi, LIN Mingxi, ZHANG Jian. Receptor discordance between primary breast cancer and liver metastases [J]. China Oncology, 2023, 33(9): 834-843. |
[14] | WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong. The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer [J]. China Oncology, 2023, 33(9): 844-856. |
[15] | CHEN Jinjuan, WANG Xingran, LI Wenzhi, CHENG Yu, SUN Yihua, TAO Xiang, MA Fenghua, SUN Li, ZHAO Hongbo, LU Xin. Conservative surgery in stage I placental site trophoblastic tumor: a report of 10 cases and literature review [J]. China Oncology, 2023, 33(9): 857-865. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd